# Ventas, Inc.: financial statements, quarterly

VTR · NYSE · CIK 740260 · [Real estate](/sectors/real-estate.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/vtr.md) · [Financials](/companies/vtr/financials.md) · [Filings](/companies/vtr/filings.md) · [Insiders](/companies/vtr/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/vtr/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [1,150](/filings/0000740260-24-000248.md) | [1,164 d](/filings/0000740260-26-000006.md) | [1,200](/filings/0000740260-25-000155.md) | [1,201](/filings/0000740260-25-000231.md) | [1,236](/filings/0000740260-25-000277.md) | [1,287 d](/filings/0000740260-26-000006.md) | [1,358](/filings/0000740260-26-000018.md) | [1,421](/filings/0000740260-26-000024.md) | [1,489](/filings/0000740260-25-000277.md) | [1,566 d](/filings/0000740260-26-000006.md) | [1,657](/filings/0000740260-26-000018.md) | [1,730](/filings/0000740260-26-000024.md) |
| Operating income | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Interest expense | $m | [148](/filings/0000740260-24-000248.md) | [155 d](/filings/0000740260-26-000006.md) | [150](/filings/0000740260-25-000155.md) | [149](/filings/0000740260-25-000231.md) | [150](/filings/0000740260-25-000277.md) | [153 d](/filings/0000740260-26-000006.md) | [149](/filings/0000740260-26-000018.md) | [150](/filings/0000740260-26-000024.md) | [158](/filings/0000740260-25-000277.md) | [154 d](/filings/0000740260-26-000006.md) | [156](/filings/0000740260-26-000018.md) | [160](/filings/0000740260-26-000024.md) |
| Income tax | $m | [(1.7)](/filings/0000740260-24-000248.md) | [4.7 d](/filings/0000740260-26-000006.md) | [(3.0)](/filings/0000740260-25-000155.md) | [7.8](/filings/0000740260-25-000231.md) | [3.0](/filings/0000740260-25-000277.md) | [(45.5) d](/filings/0000740260-26-000006.md) | [(10.6)](/filings/0000740260-26-000018.md) | [3.9](/filings/0000740260-26-000024.md) | [(6.3)](/filings/0000740260-25-000277.md) | [(1.1) d](/filings/0000740260-26-000006.md) | [(15.9)](/filings/0000740260-26-000018.md) | [(25.6)](/filings/0000740260-26-000024.md) |
| Net income | $m | [(69.6)](/filings/0000740260-24-000248.md) | [(84.7) d](/filings/0000740260-26-000006.md) | [(12.5)](/filings/0000740260-25-000155.md) | [21.2](/filings/0000740260-25-000231.md) | [21.0](/filings/0000740260-25-000277.md) | [58.7 d](/filings/0000740260-26-000006.md) | [48.4](/filings/0000740260-26-000018.md) | [71.5](/filings/0000740260-26-000024.md) | [68.7](/filings/0000740260-25-000277.md) | [73.0 d](/filings/0000740260-26-000006.md) | [59.0](/filings/0000740260-26-000018.md) | [72.2](/filings/0000740260-26-000024.md) |
| Diluted EPS | $ per share | [(0.18)](/filings/0000740260-24-000248.md) | not reported | [(0.04)](/filings/0000740260-25-000155.md) | [0.05](/filings/0000740260-25-000231.md) | [0.05](/filings/0000740260-25-000277.md) | not reported | [0.10](/filings/0000740260-26-000018.md) | [0.15](/filings/0000740260-26-000024.md) | [0.14](/filings/0000740260-25-000277.md) | not reported | [0.11](/filings/0000740260-26-000018.md) | [0.14](/filings/0000740260-26-000024.md) |
| Basic EPS | $ per share | [(0.18)](/filings/0000740260-24-000248.md) | not reported | [(0.04)](/filings/0000740260-25-000155.md) | [0.05](/filings/0000740260-25-000231.md) | [0.05](/filings/0000740260-25-000277.md) | not reported | [0.11](/filings/0000740260-26-000018.md) | [0.15](/filings/0000740260-26-000024.md) | [0.14](/filings/0000740260-25-000277.md) | not reported | [0.12](/filings/0000740260-26-000018.md) | [0.14](/filings/0000740260-26-000024.md) |

- Revenue: us-gaap:Revenues
- Operating income: not reported
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:ProfitLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $bn | [0.4](/filings/0000740260-23-000188.md) | [0.5](/filings/0000740260-25-000052.md) | [0.6](/filings/0000740260-24-000139.md) | [0.6](/filings/0000740260-24-000200.md) | [1.1](/filings/0000740260-24-000248.md) | [0.9](/filings/0000740260-26-000006.md) | [0.2](/filings/0000740260-25-000155.md) | [0.6](/filings/0000740260-25-000231.md) | [0.2](/filings/0000740260-25-000277.md) | [0.7](/filings/0000740260-26-000024.md) | [0.2](/filings/0000740260-26-000018.md) | [0.2](/filings/0000740260-26-000024.md) |
| Total assets | $bn | [25.0](/filings/0000740260-23-000188.md) | [24.7](/filings/0000740260-25-000052.md) | [24.7](/filings/0000740260-24-000139.md) | [24.5](/filings/0000740260-24-000200.md) | [25.3](/filings/0000740260-24-000248.md) | [26.2](/filings/0000740260-26-000006.md) | [26.0](/filings/0000740260-25-000155.md) | [26.5](/filings/0000740260-25-000231.md) | [26.9](/filings/0000740260-25-000277.md) | [27.6](/filings/0000740260-26-000024.md) | [27.7](/filings/0000740260-26-000018.md) | [29.7](/filings/0000740260-26-000024.md) |
| Total liabilities | $bn | [14.8](/filings/0000740260-23-000188.md) | [14.9](/filings/0000740260-25-000052.md) | [14.9](/filings/0000740260-24-000139.md) | [14.6](/filings/0000740260-24-000200.md) | [15.2](/filings/0000740260-24-000248.md) | [15.0](/filings/0000740260-26-000006.md) | [14.2](/filings/0000740260-25-000155.md) | [14.6](/filings/0000740260-25-000231.md) | [14.2](/filings/0000740260-25-000277.md) | [14.6](/filings/0000740260-26-000024.md) | [14.1](/filings/0000740260-26-000018.md) | [14.4](/filings/0000740260-26-000024.md) |
| Long-term debt | $bn | not reported | [13.5](/filings/0000740260-25-000052.md) | not reported | not reported | not reported | [13.5](/filings/0000740260-26-000006.md) | not reported | not reported | not reported | [13.0](/filings/0000740260-26-000006.md) | not reported | not reported |
| Short-term borrowings | $bn | [0.0](/filings/0000740260-23-000188.md) | [0.0](/filings/0000740260-25-000052.md) | [0.0](/filings/0000740260-24-000139.md) | [0.0](/filings/0000740260-24-000200.md) | [0.0](/filings/0000740260-24-000248.md) | [0.0](/filings/0000740260-26-000006.md) | [0.2](/filings/0000740260-25-000155.md) | [0.0](/filings/0000740260-25-000231.md) | [0.0](/filings/0000740260-25-000277.md) | [0.0](/filings/0000740260-26-000024.md) | [0.1](/filings/0000740260-26-000018.md) | [0.3](/filings/0000740260-26-000024.md) |
| Shareholders' equity | $bn | [9.8](/filings/0000740260-23-000188.md) | [9.5](/filings/0000740260-25-000052.md) | [9.4](/filings/0000740260-24-000139.md) | [9.6](/filings/0000740260-24-000200.md) | [9.8](/filings/0000740260-24-000248.md) | [10.8](/filings/0000740260-26-000006.md) | [11.5](/filings/0000740260-25-000155.md) | [11.5](/filings/0000740260-25-000231.md) | [12.4](/filings/0000740260-25-000277.md) | [12.5](/filings/0000740260-26-000024.md) | [13.1](/filings/0000740260-26-000018.md) | [14.6](/filings/0000740260-26-000024.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Total assets: us-gaap:Assets
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Short-term borrowings: us-gaap:CommercialPaper
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [286 d](/filings/0000740260-24-000248.md) | [279 d](/filings/0000740260-26-000006.md) | [266](/filings/0000740260-25-000155.md) | [336 d](/filings/0000740260-25-000231.md) | [354 d](/filings/0000740260-25-000277.md) | [374 d](/filings/0000740260-26-000006.md) | [321](/filings/0000740260-26-000018.md) | [475 d](/filings/0000740260-26-000024.md) | [379 d](/filings/0000740260-25-000277.md) | [472 d](/filings/0000740260-26-000006.md) | [395](/filings/0000740260-26-000018.md) | [557 d](/filings/0000740260-26-000024.md) |
| Capital expenditure | $m | not reported | not reported | [170](/filings/0000740260-24-000139.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Dividends paid | $m | [181 d](/filings/0000740260-24-000248.md) | [181 d](/filings/0000740260-26-000006.md) | [183](/filings/0000740260-25-000155.md) | [182 d](/filings/0000740260-25-000231.md) | [186 d](/filings/0000740260-25-000277.md) | [189 d](/filings/0000740260-26-000006.md) | [199](/filings/0000740260-26-000018.md) | [217 d](/filings/0000740260-26-000024.md) | [218 d](/filings/0000740260-25-000277.md) | [226 d](/filings/0000740260-26-000006.md) | [230](/filings/0000740260-26-000018.md) | [253 d](/filings/0000740260-26-000024.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets
- Dividends paid: us-gaap:PaymentsOfDividendsCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [404](/filings/0000740260-23-000188.md) | [404](/filings/0000740260-24-000139.md) | [404](/filings/0000740260-24-000200.md) | [407](/filings/0000740260-24-000248.md) | [407](/filings/0000740260-25-000155.md) | [412](/filings/0000740260-25-000231.md) | [419](/filings/0000740260-25-000277.md) | [446](/filings/0000740260-26-000018.md) | [459](/filings/0000740260-26-000024.md) | [463](/filings/0000740260-25-000277.md) | [487](/filings/0000740260-26-000018.md) | [498](/filings/0000740260-26-000024.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 512,946,359 at 2026-07-28, from the cover of the [10-Q filed 2026-07-30](/filings/0000740260-26-000024.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:23 ET. No prices; not investment advice.